Chimeric cancer models

US7622630B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Joerg Heyer · Cambridge, US
• Murray Robinson · Malibu, US
• William Rideout · Cambridge, US
• Ronald A. DePinho · Brookline, US
• Steven C. Clark · Shorewood, US
• Yinghui Zhou · Belmont, US
• Tyler E. Jacks · Newton, US
• Ronan O'Hagan · Waltham, US

Key dates

• Filing date: Aug 27, 2004
• Grant date: Nov 24, 2009
• Expiry date: Dec 22, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/003
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.